A Balanced Plan for Fiscal Stability and Economic Growth
Our plan seeks to achieve long-term fiscal stability and promote economic growth by aligning federal spending and revenue and pursuing market-based policy reforms.
Despite Headwinds, Biosimilars Market Is Growing in 2024
The Food and Drug Administration (FDA) has approved a record number of biosimilars in 2024, and the year is only half over.
IRS says it will deny most claims of pandemic tax credit for employers
“A big responsibility is falling on the IRS to deal with this problem, when, in fact, Congress could be dealing with this problem,” Brill said.”
Federal Debt: The Baseline and Options for Reform
On May 13, experts convened at AEI to discuss the United States’ fiscal trajectory: how we got here, where we’re going, and what we can do to reduce the burden of debt for future generations.
Current and Future State of US Biosimilars
Fourteen years ago, Congress established a regulatory pathway for biosimilars, direct competitors to branded biologic drugs.
- Alex Brill Featured in Axios
- The Disparate State Impacts and Enormous Cost of a Gas Tax Holiday
- ‘Facing the Future’: Alex Brill discusses tax code and budget challenges
- 2026 Portman Center Symposium: Building an Achievable Fiscal Policy
- Senator Booker’s Costly Standard Deduction Proposal Would Reduce Charitable Giving
- FDA Continues to Expedite Biosimilar Development
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
